About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Almost 300 million people globally have chronic hepatitis B
The company is already marketing the 4 mg and 10 mg strengths
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Positive opinions based on significant survival benefit
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
